Betamethasone will be studied for treatment of postoperative pain and discomfort after operations for inguinal hernia.
Conditions
Interventions
Trade Name: Betapred
Product Name: Betamethasone injection fluid
Pharmaceutical Form: Injection*
Pharmaceutical form of the placebo: Injection*
Route of administration of the placebo: Intravenous bolu
Sponsors
Landstinget Dalarna
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adults 18-70 years old, sheduled for inguinal hernia repair in Ludvika Hospital, after patient information requierd from regional ethical committee. Are the trial subjects under 18? Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Allergy against paracetamol, NSAID, salicylic acid, sulfonamide, betamethasone. Heart failure, kidney failure, active gastro-duodenal ulcus, serious gastrointestinal bleeding previously, liver failure, active infection, tuberculosis, psychosis, diabetes mellitus, pregnancy, breast feeding, serious systemic disease, diuretic medication, ACE-inhibitor medication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Betamethasone´s effect on postoperative pain, discomfort, wellbeing after operations for inguinal hernia repair.;Secondary Objective: Betamethasone´s effect on long lasting pain after operations for inguinal hernia repair.;Primary end point(s): Evaluation of one group treated with active substance betamethasone and other group treated with placebo will be made after 400 patients. | — |
Countries
Sweden
Outcome results
None listed